Your Location:
Home >
Browse articles >
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
REVIEW | Updated:2023-05-10
    • DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits

    • Michael Razavi , Ying-Ying Wei , Xiao-Quan Rao , Ji-Xin Zhong
    • Military Medical Research Vol. 10, Issue 2, Pages: 227-241(2023)
    • DOI: 10.1186/s40779-022-00410-2     

      CLC:

    Scan QR Code

  •  
  •  
  • Full Text(HTML)

  • Figs( 2 ) Tabs( 3 )

  • References

  • Publication Info

  • Metrics

Sections
icon
The trial reading is over, you can activate your VIP account to continue reading.
Deactivate >
icon
The trial reading is over. You can log in to your account, go to the personal center, purchase VIP membership, and read the full text.
Already a VIP member?
Log in >

38

Views

25

Downloads

0

CSCD

Alert me when the article has been cited
Submit
Tools
  • BibTeXDownload
  • EndnoteDownload
  • RefMan Download
  • NoteExpressDownload
  • NoteFirstDownload

Related Articles

Octopus-inspired engineered bacteria with a plug-and-play surface display system achieves enhanced tumor-specific colonization and antitumor immunity
Metabolic syndrome and risk of sepsis and sepsis-related mortality: evidence from two large prospective cohort studies
Engineered exosomes for diabetic foot ulcers: lessons learned, challenges remain
Frostbite: diagnosis, treatment, prognosis, and future directions
Maladaptive reorganization of mediodorsal thalamus as a central mechanism in neuropathic pain-related sleep disorders

Related Author

No data

Related Institution

No data